SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Domestic pharmaceutical industry likely to witness revenue growth of 6-8% in FY24: ICRA

17 Mar 2023 Evaluate

Rating agency ICRA in its latest report has said that domestic pharmaceutical industry is expected to witness a revenue growth of 6-8 per cent in the next fiscal (FY24). Despite several disruptive events, the Indian pharmaceutical market (IPM) witnessed a healthy CAGR of 10.9 per cent between FY2012 and FY2022.

According to the report, structural factors such as ageing population and continued rise in lifestyle/chronic diseases, in addition to WPI-linked price hikes for NLEM products, new product introductions, and annual price hikes for non-NLEM products, are expected to support revenue growth for the industry. It stated that since FY2018, IPM growth has largely been supported by price increases and new product introductions, even as volume growth remained between 2-3 per cent each fiscal. It said higher sales of anti-infectives, further supported by price increases taken to offset raw material cost inflation, aided the overall IPM growth of 14.6 per cent in FY2022. However, it said given the high base, the volume contracted by 1.2 per cent for the nine-month period of FY2023.

The report further said the steps being taken by the companies towards new product introductions and enhancements in field force are expected to support their growth going forward. It noted that drugs listed under National List of Essential Medicines (NLEM) accounted for 17-18 per cent of the IPM, with some companies deriving around 30 per cent of their revenues from such medications. In terms of emerging trends in the industry, e-pharmacies have gained significant traction in recent years and now account for 10-15 per cent of the IPM currently.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×